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Introduction
Bcr/Abl-negative myeloproliferative neoplasms (MPNs) are 
clonal hematopoietic stem cell disorders characterized by 
the proliferation of particular hematopoietic lineages with-
out blockage in cell maturation. They include polycythemia 
vera, essential thrombocythemia, and primary myelofibrosis 
(1). JAK2 is the most common MPN driver gene. JAK2V617F is a 
gain-of-function mutation that leads to growth factor hypersen-
sitivity, detected in about 70% of MPNs (95% in polycythemia 
vera and 50%–60% in essential thrombocythemia and prefi-
brotic/primary myelofibrosis) (1). JAK2V617F appears in pluripo-
tent hematopoietic progenitor cells and is present in all eryth-
roid and myeloid lineages (1). In addition, several groups have 
described JAK2V617F in endothelial cells in the liver and spleen of 
patients with splanchnic vein thrombosis (2, 3) and in circulat-
ing endothelial progenitor cells (4–6).
About 30% of MPNs are revealed by cardiovascular events. 
Cardiovascular diseases (CVDs) are the first cause of morbidity 
and mortality in patients with MPNs (7). Arterial events repre-
sent 60%–70% of these cardiovascular events (7). Interestingly, 
myocardial infarction without significant coronary stenosis by 
angiography was observed in 21% of patients with MPN (8) ver-
sus 3% in a similar population without MPN (9). This observation 
prompted the European Society of Cardiology to recommend 
searching for MPNs in the case of myocardial infarction without 
obstructive coronary artery disease (10). The mechanism under-
lying this link between myocardial infarction without obstructive 
coronary artery disease and MPNs is unknown, but a vasoactive 
phenomenon (local intense vasoconstriction) is suspected (11, 12). 
Therefore, the purpose of the present study was to examine the 
consequences of JAK2V617F mutation on arterial vascular reactivity.
Results
Increased arterial contraction in mice carrying Jak2V617F in hematopoi-
etic and endothelial cells. As JAK2V617F is present in both hematopoiet-
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presence of the Jak2V617F mutation in hematopoietic, but not endo-
thelial, cells is responsible for the increase in arterial contraction 
in response to vasoconstrictors we observed in Jak2V617F HC-EC 
mice (Figure 1, E–G).
Increased arterial contraction induced by microvesicles from 
JAK2V617F patients. We then sought to identify the mediators respon-
sible for the increased response to vasoconstrictors when JAK2V617F 
was present in hematopoietic cells and tested the hypothesis that 
circulating blood might convey biological information from hema-
topoietic cells to the vascular wall. Circulating microvesicles, i.e., 
extracellular vesicles having a size ranging from 0.1 to 1 μm, are 
now recognized as triggers of various types of vascular dysfunc-
tion (16). We therefore examined the effect of circulating microve-
sicles isolated from the blood of patients with MPN on vascular 
responses to vasoactive agents. We isolated plasma microvesicles 
from 7 patients carrying JAK2V617F (2 males, 5 females; blood drawn 
before introduction of cytoreductive therapy) and from 5 healthy 
control individuals (2 males, 3 females; age not significantly dif-
ferent from that of patients). We incubated these microvesicles 
at their plasma concentration with aortic rings from WT mice 
and observed that plasma microvesicles from patients carrying 
JAK2V617F reproduced the increased response to phenylephrine 
(Figure 3A). Plasma without microvesicles from the same patients 
and controls had no effect (data not shown).
Increased arterial contraction induced by erythrocyte-derived 
microvesicles from Jak2V617F mice. We then sought to determine the 
subpopulation of microvesicles responsible for this increased arte-
rial contraction. We generated microvesicles from each type of 
blood cell from Jak2V617F HC-EC mice or littermate controls and 
incubated these microvesicles, at the same concentration, with aor-
tic rings from WT mice. Erythrocyte-derived microvesicles gener-
ated from Jak2V617F HC-EC mice reproduced the increased response 
to phenylephrine on aortic rings ex vivo (Figure 3E), while platelet, 
PBMC, and polymorphonuclear cell (PMNC) microvesicles did not 
(Figure 3, B–D). Likewise, in vivo, femoral arteries from WT mice 
injected with microvesicles derived from JAK2V617F erythrocytes 
displayed an increased response to phenylephrine as compared 
with WT mice injected with microvesicles derived from erythro-
cytes of littermate controls (Figure 3F). Microvesicles generated 
from Jak2V617F HC-EC mouse erythrocytes carried Jak2V617F mRNA 
(Figure 3G). To investigate the interaction of erythrocyte-derived 
microvesicles with endothelial cells, we labeled microvesicles with 
the fluorescent dye PKH26, incubated them with endothelial cells, 
and performed confocal microscopy on endothelial cells. Fluores-
cence was detected in endothelial cells, suggesting that erythro-
cyte-derived microvesicles were taken up by endothelial cells (Fig-
ure 3, H and I, and ref. 17). No difference in uptake was observed 
between microvesicles from Jak2V617F HC-EC erythrocytes and their 
WT counterparts (Figure 3, H and I).
We then sought to determine whether the increased number 
of erythrocytes could in itself explain this effect or if qualitative 
changes were involved. We generated a mouse model of polycy-
themia without Jak2V617F caused by chronic epoetin injections. 
After 3 weeks of epoetin treatment, hemoglobin reached a level 
similar to that in Jak2V617F HC-EC mice (18.5 g/dL, IQR 16.5–19.5, 
vs. 17.6 g/dL, IQR 15.7–19.7; n = 5 and n = 13, respectively; P = 0.67). 
However, this model with a high number of circulating erythro-
ic and endothelial cells in patients with MPN (2, 3), we first investi-
gated vasoactive response in a mouse model mimicking the human 
disease. We generated mice expressing JAK2V617F in hematopoietic 
and in endothelial cells by crossing Jak2V617F Flex/WT mice with VE- 
cadherin-Cre mice. As expected, Jak2V617F Flex/WT VE-cadherin-Cre 
mice, herein referred to as Jak2V617F HC-EC mice, in which VE- 
cadherin was expressed during early embryonic life in a precursor 
of both endothelial and hematopoietic cells (13), developed MPN, 
as attested by higher spleen weight (2.3%–5.7% of body weight vs. 
0.3%–0.6% for littermate controls; P < 0.0001) and higher hemo-
globin levels and platelet and WBC counts than in littermate con-
trols (Figure 1, A–D). Endothelial and hematopoietic progenitor cell 
recombination was verified by crossing VE-cadherin-Cre with mTmG 
mice (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI124566DS1).
In myography assays, we observed ex vivo that aortas from 
Jak2V617F HC-EC mice displayed a substantial increase in the 
response not only to phenylephrine (Figure 1E), but also to potas-
sium chloride (Figure 1F) and angiotensin II (Figure 1G), as com-
pared with littermate controls. Removing the endothelium sup-
pressed this increased arterial contraction (Figure 1H). Likewise, 
we observed in vivo an increased response to phenylephrine in 
femoral arteries from Jak2V617F HC-EC mice compared with litter-
mate controls (Figure 1I). Thus, Jak2V617F in endothelial and hema-
topoietic cells strongly increases arterial response to vasoconstric-
tors in an endothelium-dependent manner.
Because of the high rate of myocardial infarction without sig-
nificant coronary stenosis reported in patients with MPN (8), we 
investigated the cardiac vascular bed by performing electrocar-
diography in Jak2V617F HC-EC mice and their littermate controls. 
After intravenous injection of phenylephrine, Jak2V617F HC-EC 
mice showed electrocardiogram modifications, including brady-
cardia and arrhythmia, that are indirect signs of coronary spasm 
(ref. 14 and Figure 1, J and K).
Increased arterial contraction in mice with JAK2V617F specifi-
cally expressed in hematopoietic cells but not in endothelial cells. To 
determine whether this increased arterial contraction was due 
to JAK2V617F in endothelial cells or in hematopoietic cells, we first 
generated mice expressing JAK2V617F only in endothelial cells. We 
crossed Jak2V617F Flex/WT mice with inducible VE-cadherin-Cre-ERT2 
mice expressing the Cre recombinase after tamoxifen injection 
only in endothelial cells. As expected, Jak2V617F Flex/WT VE-cadherin- 
Cre-ERT2 (herein referred to as Jak2V617F EC) mice did not develop 
MPN (Figure 2, A–D). Adequate endothelial recombination was 
verified by crossing VE-cadherin-Cre-ERT2 mice with mTmG mice 
(Supplemental Figure 1). We previously demonstrated the absence 
of hematopoietic recombination in this model (15). We observed 
no difference in arterial response to phenylephrine between the 
Jak2V617F EC mice and littermate controls (Jak2WT) (Figure 2E).
To assess the implication of JAK2V617F in hematopoietic cells, 
we generated mice expressing Jak2V617F only in hematopoietic cells 
by transplanting into lethally irradiated C57BL/6 mice Jak2V617F 
bone marrow cells obtained from Jak2V617F HC-EC mice. Irradiat-
ed C57BL/6 mice transplanted with Jak2WT BM cells were used as 
controls. Hematopoietic expression of JAK2V617F induced an MPN 
(Figure 2, F–I) and an increased arterial response to phenylephrine 
(Figure 2J). Taken together, these findings demonstrate that the 
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Jak2V617F HC-EC mice and littermate controls, either ex vivo or in 
vivo (Figure 4, C and D). We also observed that, after preincuba-
tion with the NOS inhibitor l-NAME, aortas from Jak2V617F HC-EC 
mice had a response to phenylephrine similar to that of littermate 
controls (Figure 4E). Therefore, these results demonstrate that the 
increased arterial contraction observed in Jak2V617F HC-EC mice 
resulted from a dysfunctional endothelial NO pathway.
Because previous work showed that heme in erythrocyte microve-
sicles can scavenge NO (18, 19), we quantified heme in microvesicles 
derived from Jak2V617F HC-EC mice and control mouse erythrocytes, 
but observed no difference (Supplemental Figure 2).
We then investigated generation of ROS, i.e., inhibitors of NOS 
activity and NO bioavailability (20), and found that there was 4 
times more ROS in the aortic endothelium of Jak2V617F HC-EC mice 
cytes failed to reproduce the increased response to phenylephrine 
observed in Jak2V617F HC-EC mouse aortas (Figure 3J). Thus, the 
presence of the Jak2V617F mutation in erythrocyte-derived microve-
sicles was required to cause increased arterial contraction.
NO pathway inhibition and increased endothelial oxidative stress. 
We then investigated how microvesicles derived from JAK2V617F 
erythrocytes increase the response to vasoconstrictive agents. 
We first examined the NO pathway. We observed ex vivo on aor-
tas and in vivo on femoral arteries that dilatation was impaired in 
response to acetylcholine in Jak2V617F HC-EC mice, reproducing the 
human disease (Figure 4, A and B). This impaired dilatation capac-
ity was not due to decreased sensitivity to NO of vascular smooth 
muscle cells, as the response to a direct NO donor (S-nitroso- 
N-acetyl-dl-penicillamine [SNAP]) was not different between 
Figure 1. JAK2V617F in hematopoietic and endothelial cells increases arterial contraction in an endothelium-dependent manner. (A) Representative image 
of the spleen. Hemoglobin level (B), platelet count (C), and WBC count (D) of 8 -to 12-week-old control mice (Jak2WT, n = 13) and Jak2V617F Flex/WT VE-cadherin- 
Cre mice (Jak2V617F HC-EC, n = 13). Cumulative dose-response curves to phenylephrine (Jak2WT, n = 13; Jak2V617F HC-EC, n = 13) (E) and to angiotensin II (Jak2WT, 
n = 3; Jak2V617F HC-EC, n = 4) (G), and contraction response to potassium chloride (80 mmol/L) (Jak2WT, n = 13; Jak2V617F HC-EC, n = 13) of aortas with endothe-
lium (F). (H) Cumulative dose-response curves to phenylephrine of aortas without endothelium (Jak2WT, n = 6; Jak2V617F HC-EC, n = 6). (I) Diameter change 
of femoral artery after phenylephrine injection (10–3 mol/L) (Jak2WT, n = 8; Jak2V617F HC-EC, n = 8). Electrocardiogram recording before and after intravenous 
phenylephrine (Phe) injection (3 mg/kg; Jak2WT, n = 13; Jak2V617F HC-EC, n = 6) (J), with representative images of the changes observed in 5 of 6 Jak2V617F 
HC-EC versus 4 of 13 Jak2WT mice (P = 0.057) (K). Quantitative data are expressed as median with IQR, and cumulative dose-response curves are expressed 
as mean with SEM. *P < 0.05, ***P < 0.001. Cumulative dose-response curves and electrocardiogram recordings were compared using ANOVA for repeated 
measures, and other data were compared using the Mann-Whitney U test. All tests were 2 sided.
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5A, and their role in oxidative stress is summarized in Supplemen-
tal Table 1. We found two proteins that could explain the observed 
effect, one significantly deregulated (glutathione S transferase θ 
1 [GSTT1]) and one detected only in microvesicles derived from 
JAK2V617F erythrocytes (myeloperoxidase [MPO]) (Figure 5A). We 
also considered cytochrome b-245 heavy and light chain (NOX2), 
although only a few peptides were detected in microvesicles derived 
from JAK2V617F erythrocytes (1 peptide of heavy chain in 1 of 6 sam-
ples and 1 peptide of light chain in 2 of 6 samples), since NOX plays 
a key role in oxidative stress and since no NOX2 peptide was detect-
ed in microvesicles derived from JAK2WT erythrocytes. Western 
blot analyses were then performed on microvesicles derived from 
JAK2V617F and control erythrocytes to verify proteomics results. By 
Western blot, NOX2 expression evaluated by Gp91 was not signifi-
cantly different between JAK2V617F and control erythrocyte-derived 
microvesicles (Supplemental Figure 3). Levels of GSTT1, which has 
an antioxidant effect (21), was significantly lower in JAK2V617F than 
in control erythrocyte–derived microvesicles (Figure 5, B and C). 
Expression of MPO, a protein with a strong prooxidant effect (22), 
was much higher in JAK2V617F than in control erythrocyte–derived 
microvesicles (Figure 5, D and E). We then directly inhibited MPO 
in microvesicles derived from erythrocytes of Jak2V617F HC-EC mice 
before incubation with endothelial cells (HUVECs) in vitro. We 
observed that the MPO inhibitor PF06281355 completely reversed 
the increase in endothelial oxidative stress induced by Jak2V617F 
erythrocyte–derived microvesicles (Figure 5, F and G).
than that of littermate controls (Figure 4, F and G). Conversely, 
ROS generation was normal in the aortic endothelium of Jak2V617F 
EC mice, expressing JAK2V617F only in endothelial cells (Figure 4, H 
and I). Likewise, aortic endothelium from WT mice injected with 
microvesicles derived from JAK2V617F erythrocytes generated more 
reactive species than aortic endothelium from mice injected with 
microvesicles derived from littermate control erythrocytes (Figure 
4, J and K). There was no ROS generation in underlying smooth 
muscle cells in any of these experiments (data not shown). Togeth-
er, these results show that microvesicles derived from JAK2V617F 
erythrocytes induce excessive oxidative stress in endothelial cells, 
leading to decreased availability of NO.
To ascertain the implication of the increased oxidative stress 
in the increased arterial contraction in Jak2V617F HC-EC mice, we 
treated these mice with NAC (activator of the glutathione path-
way and an antioxidant) for 14 days intraperitoneally. This treat-
ment had no effect on blood cell count or spleen weight (Supple-
mental Figure 4) but normalized arterial contraction in response 
to phenylephrine (Figure 4L).
Increased endothelial oxidative stress status by myeloperoxidase in 
erythrocyte-derived microvesicles from Jak2V617F mice. To shed light on 
the mechanisms underlying the increased oxidative stress induced 
by microvesicles derived from JAK2V617F erythrocytes, we performed 
proteomic analysis of these microvesicles (data are available via 
ProteomeXchange; see Methods). All proteins involved in ROS 
detoxification or generation are shown in the volcano plot in Figure 
Figure 2. JAK2V617F specifically expressed in hematopoietic, but not endothelial, cells increases arterial contraction. (A and F) Representative images 
of the spleen. Blood cell count of 10- to 13-week-old control mice (Jak2WT, n = 7) and Jak2V617F Flex/WT VE-cadherin-Cre-ERT2 mice (Jak2V617F EC, n = 7) (B–D) 
and of 13- to 15-week-old chimeric C57BL/6 mice transplanted with bone marrow of WT mice (Jak2WT, n = 5) or of Jak2V617F HC-EC mice (Jak2V617F HC, n = 5) 
(G–I). Data are expressed as median with IQR. Cumulative dose-response curve to phenylephrine of aortas from Jak2WT (n = 7) and Jak2V617F EC mice (n = 7) 
(E) and from Jak2WT (n = 5) and Jak2V617F HC mice (n = 5) (J). Quantitative data are expressed as median with IQR, and cumulative dose-response curves are 
expressed as mean with SEM. *P < 0.05, **P < 0.01. Cumulative dose-response curves were compared using ANOVA for repeated measures, and other 
data were compared using the Mann-Whitney U test. All tests were 2 sided.
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urea significantly improved contraction in response to phenyleph-
rine as compared with vehicle (Figure 6E).
We then treated Jak2V617F HC-EC mice with ruxolitinib for 21 
consecutive days and observed a significant decrease in spleen 
weight and WBC count (Figure 6, F and I), but no effect on hemo-
globin level or platelet count (Figure 6, G and H). Ruxolitinib had 
no effect on arterial response to phenylephrine (Figure 6J).
Beyond its cholesterol-lowering effect, simvastatin also 
improves endothelial function through the NO pathway and by 
preventing oxidative stress damage (23, 24). Thus, we tested its 
effect on the arterial response to phenylephrine in Jak2V617F HC-EC 
mice. Fourteen days of treatment with simvastatin did not change 
In conclusion, JAK2V617F erythrocyte–derived microvesicles 
carry MPO, which confers a prooxidant phenotype in endotheli-
al cells, leading to the increased arterial contraction observed in 
Jak2V617F HC-EC mice.
Statins as a potential new treatment in myeloproliferative neo-
plasms. We then tested whether available treatments for MPNs, 
namely hydroxyurea and ruxolitinib, affect this increased arteri-
al contraction. In Jak2V617F HC-EC mice, which best represent the 
human disease, hydroxyurea treatment for 10 consecutive days 
decreased spleen weight, hemoglobin level, and WBC count (Fig-
ure 6, A, B, and D). However, platelet count was not affected by 
this short-duration hydroxyurea treatment (Figure 6C). Hydroxy-
Figure 3. Microvesicles derived from JAK2V617F RBCs are responsible for increased arterial contraction. (A) Cumulative dose-response curves to phenyl-
ephrine of aortas from WT mice incubated with microvesicles (MVs) isolated from JAK2V617F patients (n = 7) and control individuals (n = 5) at their circu-
lating concentration. Cumulative dose-response curves to phenylephrine of aortas from WT mice incubated with microvesicles generated from platelets 
(n = 5 and n = 5, respectively) (B), PBMCs (n = 5 and n = 6, respectively) (C), PMNCs (n = 5 and n = 5) (D), and RBCs (n = 9 and n = 4, respectively) (E) from 
Jak2V617F HC-EC mice (Jak2V617F) or littermate control mice (WT). (F) Change in diameter of femoral artery induced by phenylephrine injection (10–3 mol/L) in 
control mice previously injected with control erythrocyte–derived microvesicles (Jak2WT RBC MVs, n = 10) or with Jak2V617F erythrocyte–derived microvesicles 
(Jak2V617F RBC MVs , n = 10). (G) Allelic discrimination plot of ARN isolated from microvesicles derived from Jak2WT (in blue) and Jak2V617F erythrocytes (in 
orange) (n = 3 per group); no template control (NTC), black. Quantification (H) and representative images (I) of the uptake by endothelial cells (HUVECs 
with DAPI in blue) of erythrocyte-derived microvesicles from JAK2V617F mice (n = 5) or JAK2WT mice (n = 5) or respective 20,500-g supernatant (SNT; n = 3 for 
each group). Scale bars: 10 μm. (J) Cumulative dose-response curve to phenylephrine of aortas from WT mice injected with vehicle (n = 5) or with epoetin 
(EPO; n = 8). Quantitative data are expressed as median with IQR, and cumulative dose-response curves are expressed as mean with SEM. *P < 0.05,  
**P < 0.01. Cumulative dose-response curves were compared using ANOVA for repeated measures, and other data were compared using the Mann- 
Whitney U test. All tests were 2 sided.
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spleen weight, hemoglobin level, or platelet count (Figure 6, K–M). 
There was only a slight decrease in WBC count following simvas-
tatin treatment (Figure 6N). Interestingly, simvastatin significant-
ly improved the aortic response to phenylephrine as compared 
with vehicle (Figure 6O).
Discussion
This study demonstrated that JAK2V617F erythrocyte–derived 
microvesicles carrying MPO are responsible for increased oxida-
tive stress in arterial endothelium and decreased availability of 
NO, which strongly increased arterial contraction in response to 
vasoconstrictive agents, possibly accounting for the arterial events 
associated with MPNs. Simvastatin, a drug with antioxidant prop-
erties, improved arterial contraction.
The first major finding of our study is that JAK2V617F MPN induc-
es a considerable increase in arterial contraction. This finding sug-
gests a vasospastic phenomenon associated with MPN and thus 
represents a paradigm shift with regard to MPNs, as arterial events 
have only been seen to be a result of a thrombotic process (7). Our 
results obtained ex vivo and in vivo could explain this higher inci-
dence of arterial events in patients with polycythemia vera than 
in the general population and the high prevalence of myocardial 
infarction without significant coronary stenosis by angiography in 
patients with MPN (8). Arterial spasm is an underdiagnosed phe-
nomenon that can occur in patients without atherosclerosis, but 
underlying nonstenotic atherosclerotic plaques are also known to 
be a contributing factor. This suggests that the effect we observed 
might account not only for the myocardial infarction without 
significant coronary stenosis reported in patients with MPN, but 
might also more widely for arterial events in patients with athero-
sclerotic plaques and MPN. Moreover, arterial spasm occurs not 
only in coronary arteries, but also in brain arteries (25). We also 
Figure 4. Disturbed endothelial NO pathway and increased oxidative stress status. Cumulative dose-response curve of aortas from Jak2V617F HC-EC mice 
and littermate controls (Jak2WT) to acetylcholine (n = 11 and n = 11, respectively) (A) and to SNAP (n = 5 and n = 6, respectively) (C), and to phenylephrine 
after l-NAME incubation (n = 11 and n = 7, respectively) (E). Diameter change of femoral arteries after injection of acetylcholine (10–2 mol/L) (Jak2WT, n = 8; 
Jak2V617F HC-EC, n = 8) (B) and SNAP (10–3 mol/L) (Jak2WT, n = 4; Jak2V617F HC-EC, n = 4) (D). Quantification of ROS generation (red surface) per endothelial cell 
in control mice (Jak2WT) versus Jak2V617F HC-EC mice (F); control mice (Jak2WT) versus Jak2V617F EC mice (H); control mice injected with microvesicles derived 
from control (Jak2WT RBC MVs, n = 6) or JAK2V617F erythrocytes (Jak2V617F RBC MVs, n = 6) (J). Representative images of en face endothelial staining with Cell-
ROX (red fluorogenic probes for ROS generation) and DAPI (nuclei in blue) of aortas (G, I, and K). Scale bars: 10 μm. (L) Cumulative dose-response curve to 
phenylephrine of aortas from Jak2V617F HC-EC mice treated with vehicle (n = 5) and with NAC (n = 7). *P < 0.05, **P < 0.01, ***P < 0.001. Quantitative data 
are expressed as median with IQR and compared using the Mann-Whitney U test, and cumulative dose-response curves are expressed as mean with SEM 
and compared using ANOVA for repeated measures.
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found an impairment in arterial dilatation, which is in line with 
the altered endothelium-dependant, flow-mediated vasodilata-
tion reported in patients with polycythemia vera in the absence of 
overt arterial disease (26).
The second major finding of our work is the contribution of 
JAK2V617F erythrocyte–derived microvesicles to this increased arte-
rial contraction associated with MPN. Importantly, we observed 
this effect with JAK2V617F erythrocyte microvesicles from mice as 
well as microvesicles isolated from patients carrying JAK2V617F. 
We thus highlight here a crucial vascular role for microvesicles 
in MPNs, beyond their already described involvement in coagu-
lation in this setting (27–31). Although patients with MPNs have 
higher circulating levels of microvesicles than healthy individuals, 
we assessed vascular reactivity using the same concentrations of 
Figure 5. MPO carried by erythrocyte-derived microvesicles from Jak2V617F mice is responsible for increased endothelial oxidative stress. (A) Volcano plot 
obtained by using quantitative label-free mass spectrometry analysis of proteins isolated from microvesicles derived from JAK2V617F (n = 6) and JAK2WT (n = 
4) erythrocytes (ratio JAK2V617F/JAK2WT); only proteins involved in cellular oxidant detoxification (GO 0098869) and ROS metabolic process (GO 0072593) are 
presented (red line corresponds to P = 0.05). Representative image of GSTT1 (B) and MPO (D) Western blots performed on erythrocyte-derived microvesi-
cles, with respective quantification (C and E) (JAK2WT erythrocyte microvesicles, n = 11; JAK2V617F erythrocyte microvesicles, n = 11). (F) Quantification of ROS 
generation (red surface) per endothelial cell (HUVEC) after exposition of erythrocyte-derived microvesicles from control mice (Jak2WT) (n = 4) and Jak2V617F 
HC-EC mice and without (red, n = 4) and with (n = 4) preincubation with an MPOi (PF06281355, 5 mol/L). (G) Representative images of HUVEC staining 
with CellROX (red fluorogenic probes for ROS generation) and DAPI (nuclei in blue). Scale bars: 10 μm. *P < 0.05, ***P < 0.001. Quantitative data are 
expressed as median with IQR and compared using the Mann-Whitney U test and Kruskal-Wallis test for multiple comparisons. CY24A, cytochrome b-245 
light chain; CY24B, cytochrome b-245 heavy chain.
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from JAK2V617F erythrocytes in the increase in endothelial oxida-
tive stress. MPO is a polycationic heme-containing glycoprotein 
stored mainly in the azurophilic granules of neutrophils, but up to 
30% of total cellular MPO can be released as active enzyme into 
the extracellular space. Interestingly, extracellular MPO can bind 
to the RBC membrane and is associated with endothelial dysfunc-
tion in the context of ischemic heart disease (41–45). Our results 
demonstrate that MPO binds to erythrocyte-derived microves-
icles, and increases endothelial oxidative stress and the vascular 
response to vasoconstrictors.
The role of GSTT1 in the increased endothelial oxidative 
stress status and vascular reactivity we observed with microve-
sicles derived from JAK2V617F erythrocytes remains uncertain, 
because we could not restore a normal level of GSTT1 only in 
microvesicles. The normalization of vascular reactivity induced 
by NAC could be explained by the glutathione inducer activity of 
NAC, but could also just be due to the potent antioxidant activity 
of this drug.
microvesicles for both groups, which suggests that microvesicle 
composition, and not concentration, accounts for the observed vas-
cular effect (27, 28, 32–35). We cannot rule out the possibility that 
JAK2V617F erythrocytes themselves, in addition to microvesicles, 
also directly increase arterial contraction associated with MPNs.
Finally, we demonstrated that NO pathway inhibition and 
increased endothelial oxidative stress are implicated in this 
increased arterial contraction associated with MPN. Several groups 
have reported high levels of circulating ROS products (36–38) and 
low antioxidant status in MPN (37, 39), but endothelial oxidative 
stress has not to our knowledge been investigated. Erythrocyte 
microvesicles have already been linked to vascular dysfunction in 
various settings, such as erythrocyte storage and sickle cell disease 
(18, 19, 40), but not in the context of MPN. Thanks to proteomics 
approaches, we were able to identify a defect in GSTT1 and over-
expression of MPO in microvesicles derived from JAK2V617F eryth-
rocytes. Using direct and irreversible inhibition of MPO, we were 
able to ascertain the role of MPO carried by microvesicles derived 
Figure 6. Simvastatin improves the increased arterial contraction induced by JAK2V617F. Spleen to body weight ratio (A), hemoglobin level (B), platelet 
count (C), and WBC count (D) in Jak2V617F HC-EC mice treated with vehicle (n = 4) or hydroxyurea (HU, n = 7). Spleen to body weight ratio (F), hemoglobin 
level (G), platelet count (H), and WBC count (I) in Jak2V617F HC-EC mice treated with vehicle (n = 5) or ruxolitinib (n = 4). Spleen to body weight ratio (K), 
hemoglobin level (L), platelet count (M), and WBC count (N) in Jak2V617F HC-EC mice treated with vehicle (n = 10) or simvastatin (n = 7). Cumulative dose- 
response curves to phenylephrine of aortas from Jak2V617F HC-EC mice treated with vehicle or hydroxyurea (n = 4 and n = 7) (E), with vehicle or ruxolitinib (n 
= 5 and n = 4) (J), and with vehicle or simvastatin (n = 10 and n = 7) (O). *P < 0.05, **P < 0.01. Data are expressed as mean with SEM for cumulative curves 
and median with IQR for spleen weight and blood cell counts. Cumulative dose-response curves were compared using ANOVA for repeated measures, and 
other data were compared using the Mann-Whitney U test. All tests were 2 sided.
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(13) with Jak2V617F Flex/WT mice (50) generated by our research team. 
Mice carrying the inducible JAK2V617F mutation specifically in endothe-
lial cells were obtained by crossing VE-cadherin-Cre-ERT2 transgenic 
mice provided by R.H. Adams (Max Planck Institute for Molecular 
Biomedicine, Münster, Germany) (51) with Jak2V617F Flex/WT mice gen-
erated in-house (50). The Flex (Flip-Excision) strategy allows expres-
sion of a mutated gene in adulthood, in a temporal and tissue-specific 
manner (52). It allows an efficient and reliable Cre-mediated genetic 
switch: the expression of a given gene is turned on by inversion, while 
expression of another one is simultaneously turned off by excision. In 
all experiments, male and female mice were used.
For organ chamber experiments and femoral in vivo experiments, 
mice were euthanized between the ages of 8 and 17 weeks. For induc-
tion of the Cre recombinase expression in Jak2V617F Flex/WT VE-cadherin- 
Cre-ERT2 mice, mice were injected intraperitoneally with 1 mg/
mouse/d tamoxifen (Sigma-Aldrich, T5648) for 5 consecutive days 
over 2 consecutive weeks (10 mg in total per mouse) between the ages 
of 5 and 7 weeks. Experiments were performed between 4 and 6 weeks 
after the last tamoxifen injection. Both female and male mice were 
used for each experiment.
Verification of the efficient endothelial recombination in mouse mod-
els. All mice were on a C57BL/6 background. Mice with the mTmG 
reporter were crossed with VE-cadherin-Cre transgenic mice (both 
generated in-house) or VE-cadherin-Cre-ERT2 transgenic mice pro-
vided by R.H. Adams (51). For induction of the mTmG VE-cadherin- 
Cre-ERT2 model, mice were injected intraperitoneally with 1 mg/
mouse/d tamoxifen (Sigma-Aldrich, T5648) for 5 consecutive days 
over 2 consecutive weeks (10 mg in total per mice) between the ages 
of 5 and 7 weeks, and experiments were performed 2 weeks after the 
last injection of tamoxifen. Aortas and femurs were harvested under 
isoflurane anesthesia and fixed in 4% PFA. Aortas were mounted en 
face on glass slides, while femurs were cryosectioned. All tissues were 
imaged using a Leica SP5 confocal microscope at ×400 magnification. 
For flow cytometry analysis in mTmG VE-cadherin-Cre-ERT2 mice, 
bone marrow cells were stained with Ter-119 APC and Gr-1 APC (BD 
Biosciences, 553673) and analyzed on an Accuri C6 flow cytometer 
(BD Biosciences). Data were interpreted using BD Accuri C6 Software.
Patient inclusion. All patients fulfilling inclusion criteria were pro-
spectively included at the Hepatology Department, Beaujon Hospital, 
Clichy, France, between May and July 2016. Only patients carrying 
JAK2V617F without specific treatment for MPNs were included. All patients 
had a history of Budd-Chiari syndrome or portal vein thrombosis and 
were receiving vitamin K antagonists. Controls were healthy volunteers.
Organ chamber experiments. Thoracic aortas from adult mice were 
isolated after animal sacrifice under 2% isoflurane anesthesia. The 
aortic rings were mounted immediately in organ chambers (Multi 
Wire Myograph System, DMT, model 610M) filled with Krebs-Ringer 
solution ( 118.3 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L MgSO4, 
1.2 mmol/L KH2PO4, 1.25 mmol/L CaCl2, 25.0 mmol/L NaHCO3, 5.0 
mmol/L, and glucose) and gassed with a mixture of 95% O2 and 5% 
CO2 (pH 7.4). The presence of functional endothelial cells was con-
firmed by relaxation to acetylcholine chloride (Sigma-Aldrich, A6625) 
(10–5 mol/L) following a contraction evoked by phenylephrine (10–7 
mol/L), defined as a relaxation ≥70% of the precontraction as pre-
viously described (49). After extensive washout and equilibration, 
contraction to phenylephrine hydrochloride (concentration-response 
curve, 10–9 to 10–4 mol/L) (Sigma-Aldrich, P1250000), angiotensin II 
In addition to demonstrating how JAK2V617F induces this 
increased arterial contraction, our results open potential thera-
peutic perspectives to prevent cardiovascular events in patients 
with MPN. We demonstrated that simvastatin, a well-known and 
easily accessible drug, strongly improved the arterial response to 
a vasoconstrictive agent in our MPN mouse model. These results 
thus pave the way for testing the use of simvastatin to prevent 
arterial events in patients with MPN. We also tested available 
treatments for MPN and observed that hydroxyurea, but not 
ruxolitinib, improved arterial contraction. This difference might 
be explained by the fact that hydroxyurea decreased erythrocyte 
counts in our mouse model, whereas ruxolitinib did not (46, 47).
In conclusion, our study showed that microvesicles derived 
from erythrocytes are responsible for increased arterial contrac-
tion in JAK2V617F MPNs. This effect is due to overexpression of MPO 
in JAK2V617F erythrocyte–derived microvesicles, which is responsi-
ble for increased endothelial oxidative stress and NO pathway inhi-
bition. Simvastatin appears to represent a new treatment approach 
to prevent arterial events in MPN, which warrants further study.
Methods
Experimental design. The objective of our study was to analyze endothe-
lial reactivity in MPN. We first noticed a substantial increase in arterial 
contraction in Jak2V617F HC-EC mice, a model with Jak2V617F expression 
in both hematopoietic and endothelial cells that mimics the human dis-
ease. We created mouse models specifically mutated in endothelial or 
hematopoietic cells. We then searched for the mediators responsible for 
the increased response to vasoconstrictors when Jak2V617F was present 
in hematopoietic cells; we tested the hypothesis that circulating blood 
might convey biological information from hematopoietic cells to the 
vascular wall, and focused on microvesicles. We identified that eryth-
rocyte-derived microvesicles were responsible for this effect and per-
formed mass spectrography analysis to identify the proteins involved. 
Sample size was chosen based on previous works using the same tech-
nique (myography) and microvesicles published by our team (48, 49).
Mouse breeding occurred in our animal facility in accordance 
with local recommendations. Control mice were matched with litter-
mates of the appropriate, age, sex, and genetic background to account 
for any variation in data.
Numbers of experimental replicates are shown in the figure leg-
ends, and at least 3 independent experiments were performed. For 
each myography experiment, duplicates with the same aorta were 
used, averaged, and counted as n = 1. There was no randomization in 
these experiments. We did not exclude any samples other than those 
not fulfilling the quality criteria detailed in Organ chamber experiments. 
Indeed, only aortas with a viable endothelium were used for myogra-
phy (i.e., relaxation to acetylcholine ≥70% of the precontraction).
For human samples, inclusion and exclusion criteria were defined 
before sample collection (see Patient inclusion). No outlier was exclud-
ed. Investigators were not blinded to group allocation during col-
lection and analysis of the data. Donors included patients carrying 
JAK2V617F with a past history of splanchnic vein thrombosis who had 
not received any specific treatments other than vitamin K antagonists, 
and healthy volunteers.
Murine models. All mice were on a C57BL/6 background. Mice car-
rying a constitutive Jak2V617F mutation in endothelial and hematopoi-
etic cells were obtained by crossing VE-cadherin-Cre transgenic mice 
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gations at 15,000 g for 1 minute, and the supernatants were collected. 
Microvesicles were isolated as described above using a 20,500-g cen-
trifugation during 45 minutes. Concentrations of annexin V–positive 
microvesicles (as described above) were analyzed in the PFP and the 
20,500-g microvesicle pellet for each mouse.
To isolate platelets, 500 μL of whole blood was diluted in 10 mL PBS. 
A 1.063-g/mL density barrier was created by combining 5 mL of 1.320 g/
mL 60% iodixanol stock solution (OptiPrep density gradient medium, 
Sigma-Aldrich) with 22 mL diluent (0.85% NaCl, 20 mM HEPES-NaOH, 
pH 7.4, 1 mM EDTA). For platelet separation, 10 mL diluted blood from 
control and Jak2V617F HC-EC mice was layered over a 10-mL density bar-
rier and centrifuged at 350 g for 15 minutes at 20°C with the brake turned 
off. The interface between the density barrier and the blood contained 
platelets. Residual contaminating erythrocytes were removed by mag-
netic sorting. Briefly, the cell suspension was labeled with Anti-Ter-119 
MicroBeads (Miltenyi Biotec, 130-049-901), and erythrocytes (Ter-119–
positive) were negatively sorted using a MACS Separator. The remain-
ing cells (platelets) were subsequently washed with PBS and exposed 
to 5 μmol/L ionomycin in TBS for 30 minutes at 37°C. 5 mM EDTA was 
then added to chelate free calcium. Finally, cells were discarded by cen-
trifugation at 15,000 g for 1 minute, the supernatant was collected, and 
microvesicles were isolated, as described above.
Vascular reactivity following exposure to microvesicles. For organ 
chamber experiments, thoracic aortas from adult C57BL/6 mice (8–10 
weeks old) were isolated after sacrifice under isoflurane anesthesia. 
Mouse aortic rings were incubated for 24 hours at 37°C in a 5% CO2 
incubator, with filtered DMEM supplemented with antibiotics (100 
IU/mL streptomycin, 100 IU/mL penicillin [Gibco, Invitrogen], and 
10 μg/mL polymyxin B [Sigma-Aldrich]) in the presence of microvesi-
cles. Aortic rings were then mounted in organ chambers, and concen-
tration-response curves to pharmacological agents were performed.
For in vivo femoral artery experiments, C57BL/6 mice were inject-
ed intravenously (retro-orbital injection) with microvesicles (100 μL 
final volume with 2 μL heparin sodium [5000 IU/mL]). Experiments 
were performed 2 hours after injection.
Microvesicles from patients and healthy controls were incubated 
at their respective individual plasma concentration (annexin V–posi-
tive microvesicles). Microvesicles generated from mice were incubat-
ed or injected at the same final concentration as for Jak2V617F HC-EC 
mice and control mice, namely 7000 annexin V–positive microvesi-
cles/μL for erythrocyte- and platelet-derived microvesicles and 700 
annexin V–positive microvesicles/μL for PBMC- and PMNC-derived 
microvesicles. We chose these concentrations because we found in 
preliminary experiments that the majority of mice had concentrations 
of annexin V–positive microvesicles between 1000 and 10,000/μL, 
and because PBMC- and PMNC-derived microvesicles are consistent-
ly found to be less abundant in the blood than erythrocyte- and plate-
let-derived microvesicles (27, 32).
Bone marrow transplantation. We subjected 6- to 8-week-old 
C57BL/6J mice to medullar aplasia following lethal 9.5-Gy total body 
irradiation. We repopulated the mice with an intravenous injection of 
bone marrow cells isolated from femurs and tibiae of age-matched 
Jak2V617F HC-EC and littermate control mice. Medullar reconstitution 
was allowed for 8 weeks before experiments were performed.
Treatments. Hydroxyurea (Sigma-Aldrich, H8627) or the same 
volume of vehicle (0.9% NaCl) was administrated for 10 consecutive 
days (100 mg/kg/d bid) by intraperitoneal injections.
(concentration-response curve, 10−9 to 10−6 mol/L) (Sigma-Aldrich, 
A9525), or KCl (80 mmol/L) and relaxation to acetylcholine chloride 
(concentration-response curve, 10−9 to 10−4 mol/L) or SNAP (Sigma- 
Aldrich, N3398) (concentration-response curve, 10−10 to 10−5 mol/L) 
was studied. For NO synthase inhibition, aorta rings were preincubat-
ed for 45 minutes with 10–4 mol/L l-NAME (Cayman, 80210) before 
concentration-response curve to phenylephrine without washout were 
performed. In some experiments, the endothelium was mechanically 
removed by inserting the tip of forceps within the lumen and gently 
rubbing the ring back and forth on a piece of wet tissue. For the NAC 
experiment (commercial HIDONAC, Zambon), NAC was added to 
the Krebs-Ringer solution at a final concentration of 20 mmol/L.
In vivo femoral reactivity. The femoral artery of adult mice was 
exposed under 2% isoflurane anesthesia. Krebs-Ringer solution (see 
Organ chamber experiments) gassed with a mixture of 95% O2and 5% 
CO2 (pH 7.4) at 37°C was permanently superfused (2 mL/min) on 
the exposed artery. After a 15-minute equilibration, arterial respons-
es were determined by addition of phenylephrine (10−3 mol/L) for 2 
minutes, then acetylcholine (10−1 mol/L) for 1 minute (Sigma-Aldrich). 
On the contralateral leg, with the same protocol, KCl (80 mmol/L) 
and then SNAP (10−3 mol/L) were used. All dilutions were prepared 
just before application. Changes in vessel diameter were continuously 
recorded on a videotape recorder. Subsequently, images were export-
ed and vessel outer diameters analyzed using ImageJ (NIH) software.
Isolation and characterization of patients’ circulating microvesicles. 
Circulating microvesicles from patients or healthy control individ-
uals were isolated from platelet-free plasma obtained by successive 
centrifugations of venous blood, as reported previously (53). Briefly, 
citrated venous blood (15 mL) was centrifuged twice at 2500 g for 15 
minutes (at room temperature) to remove cells and cell debris and to 
obtain platelet-free plasma (PFP). A portion of this PFP was then ali-
quoted and stored at –80°C. The rest was centrifuged at 20,500 g for 
2 hours (4°C). Supernatant of this 20,500 g centrifugation was then 
discarded, and the resulting microvesicles pellet was resuspended in 
a minimal volume of supernatant, aliquoted, and stored at –80°C. For 
each patient, concentrations of annexin V–positive microvesicles were 
analyzed in the PFP and the resuspended pellet of microvesicles.
Circulating levels of annexin V–positive microvesicles (Beckman 
Coulter, IM3614) were determined on a Gallios flow cytometer (Beck-
man Coulter) using a technique previously described in detail (49, 53).
Generation of microvesicles from mice. Blood samples were collected 
from the inferior vena cava of Jak2V617F HC-EC mice or littermate con-
trols using a 25 G × 1 inch needle in a 1-mL syringe precoated with 3.8% 
sodium citrate. PFPs were generated as described above for patients 
and used to measure plasma annexin V–positive microvesicles in mice. 
The pelleted cells obtained following the first 2500-g centrifugation 
were resuspended in PBS to a final volume of 5 mL for control mice 
and 10 mL for Jak2V617F HC-EC mice. PBMCs, PMNCs, and erythro-
cytes were separated using a double Percoll gradient (63% and 72% 
for control mice, and 63% and 66% for Jak2V617F HC-EC mice) using a 
700-g centrifugation for 25 minutes, without braking. The slight dif-
ferences between the protocols used for control and Jak2V617F HC-EC 
mice were the result of the preliminary experiments we performed to 
obtain pure isolation of each cell type. Cells were subsequently washed 
with PBS, then incubated with 5 μmol/L ionomycin in TBS for 30 min-
utes at 37°C to induce microvesicle generation. 5 mmol/L EDTA was 
added to chelate free calcium. Cells were then discarded by centrifu-
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with medium and paraformaldehyde (4%, 5 minutes), HUVECs were 
costained with DAPI (0.1 μg/mL, Sigma-Aldrich) in order to identify 
nuclei. Images were acquired using a Leica SP8 confocal microscope 
at ×400 magnification.
Electrocardiography. Electrocardiograms were recorded from mice 
using noninvasive ecgTUNNEL (Emka Technologies) with minimal 
filtering. ECG signal was continuously monitored for 3 minutes (base-
line). Waveforms were recorded using Iox Software, and heart rate and 
intervals were measured with ecgAUTO from recording traces. Follow-
ing baseline determination, the animals received a single administra-
tion of phenylephrine (bolus, 3 mg/kg) by the intravenous route at the 
caudal vein, and electrocardiograms were recorded 3–5 minutes more.
RNA gene allelic discrimination. Erythrocyte microvesicles were 
lysed with QIAzol lysis reagent (QIAGEN), and RNA was extracted 
with an RNeasy Micro Kit (QIAGEN) according to the manufactur-
er’s instructions. RNA was quantified with a Qubit RNA HS Assay 
Kit (Thermo Fisher Scientific). cDNA synthesis was performed 
with a QuantiTect Reverse Transcription Kit (QIAGEN). RNA gene 
allelic discrimination was performed by TaqMan analysis with the 
ABI Prism GeneAmp 7500 Sequence Detection System (Applied 
Biosystems, Invitrogen) using the following as primers: TTTA-
CAAATTCTTGAACCAGAATGTTC (JAK2 forward) and TTCT-
CACAAGCATTTGGTTTTGAAT (JAK2 reverse); and as probes: 
VIC-CTCCACAGACACAGAC-MGB for JAK2WT and 6-FAM-TCTC-
CACAGAAACAGAGA-MGB for JAK2V617F.
Mass spectrometry analysis. Size-exclusion chromatography of 
microvesicles was then performed in order to separate microvesicles 
from soluble proteins. Successive aliquot of 150 μL were collected, 
and measurement of protein absorbance was performed. Fractions 
contained in tubes 6–11, containing microvesicles, were selected and 
then centrifuged at 20–500 g for 2 hours. To finish, microvesicles were 
lysed using 1% Triton buffer.
For mass spectrometry analysis, proteins were precipitated over-
night at –20°C with 0.1 mol/L ammonium acetate glacial in 80% meth-
anol (buffer 1). After centrifugation at 14,000 g and 4°C for 15 minutes, 
the resulting pellets were washed twice with 100 μL buffer 1 and fur-
ther dried under vacuum (Savant Centrifuge SpeedVac concentrator, 
Thermo Fisher Scientific). Proteins were then reduced by incubation 
with 10 μL of 5 mmol/L DTT at 57°C for 1 hour and alkylated with 2 μL 
of 55 mmol/L iodoacetamide for 30 minutes at room temperature in 
the dark. Trypsin/LysC (Promega) was added twice at 1:100 (wt/wt) 
enzyme/substrate, at 37°C for 2 hours first and then overnight. Sam-
ples were then loaded onto a homemade C18 StageTips for desalting. 
Peptides were eluted using  40:60 MeCN/H2O plus 0.1% formic acid 
and vacuum concentrated to dryness. Online chromatography was per-
formed with an RSLCnano system (Ultimate 3000, Thermo Fisher Sci-
entific) coupled online to a Q Exactive HF-X with a Nanospray Flex ion 
source (Thermo Fisher Scientific). Peptides were first trapped on a C18 
column (75-μm inner diameter × 2 cm; nanoViper Acclaim PepMap 
100, Thermo Fisher Scientific) with buffer A (2:98 MeCN/H2O in 0.1% 
formic acid) at a flow rate of 2.5 μL/min over 4 minutes. Separation was 
then performed on a 50 cm × 75 μm C18 column (nanoViper Acclaim 
PepMap RSLC, 2 μm, 100 Å) regulated to a temperature of 50°C with a 
linear gradient of 2%–30% buffer B (100% MeCN in 0.1% formic acid) 
at a flow rate of 300 nL/min over 91 minutes. MS full scans were per-
formed in the ultrahigh-field Orbitrap mass analyzer in the m/z range 
of 375–1500 with a resolution of 120,000 at m/z 200. The 20 most 
Ruxolitinib (Jakavi, Novartis) was administered for 21 consecutive 
days (30 mg/kg, 2 times per day) by oral gavage (54). Ruxolitinib was 
prepared from 15-mg commercial tablets in PEG300/5% dextrose 
mixed at a 1:3 ratio, as previously reported (55). Control mice were 
administered the same volume of vehicle (PEG300/5% dextrose).
Simvastatin (Sigma-Aldrich, S6196) was administered for 14 days 
(20 mg/kg/d, once a day) by intraperitoneal injections. Activation by 
hydrolysis was first achieved by dissolving 50 mg in 1 mL pure ethanol 
and adding 0.813 mL of 1 mol/L NaOH. pH was adjusted to 7.2 by add-
ing small quantities of 1 mol/L HCl, and dilution was then performed in 
PBS (56). Control mice were injected with the same volume of vehicle.
Human recombinant epoetin alfa (5000 UI/kg, diluted in 0.2% 
BSA in PBS) or vehicle (0.2% BSA in PBS) was administered to WT 
mice every 2 days for 3 weeks by intraperitoneal injection, as previ-
ously described (57).
NAC (HIDONAC) diluted in 0.9% NaCl or the same volume of 
vehicle (0.9% NaCl) was administrated for 14 consecutive days (500 
mg/kg/d) by intraperitoneal injections.
Blood cell count analysis. Blood was collected on the day of sacri-
fice from the inferior vena cava using a 25G × 1 inch needle in a 1-mL 
syringe precoated with 3.8% sodium citrate. Blood count analyses 
were performed using a Hemavet 950FS analyzer (Drew Scientific).
Quantification of ROS generation. Thoracic aortas from adult mice 
were isolated after animal sacrifice under 2% isoflurane anesthesia, 
longitudinally opened, and placed directly in HBSS (Sigma-Aldrich, 
14025-092). For each set of experiments, all aortas were processed 
immediately after removal, at the same time, with the same reagents, 
and in the same manner. No plasma factor or blood cells were added 
during the ROS generation assessment. For positive and negative con-
trols, 2 pieces of WT aortas were incubated with H2O2 (100 μmol/L 
final concentration) for 20 minutes at 37°C. For negative controls, 
NAC (5 mmol/L final concentration) was incubated together with H2O2 
for 20 minutes at 37°C. All aortas were then incubated with 5 μmol/L 
CellROX (Thermo Fisher Scientific, C10422) for 30 minutes at 37°C. 
CellROX Deep Red Reagent is a fluorogenic probe designed to reliably 
measure ROS inside living cells. The cell-permeable CellROX Deep 
Red dye is nonfluorescent while outside the cell and in a reduced state 
and upon oxidation exhibits excitation/emission maxima at 640/665 
nm. After rinsing and fixation (4% paraformaldehyde, 20 minutes), 
samples were costained with DAPI (0.1 μg/mL, Sigma-Aldrich) in order 
to identify cell nuclei. After staining, aortas were washed with PBS, 
mounted en face on glass slides, and imaged using a bright-field Axio 
Imager Z1 (Zeiss) microscope. Images were acquired in the 2 hours fol-
lowing staining at ×400 magnification. CellROX-positive surface (in 
red) and cell numbers were quantified using ImageJ software.
MPO inhibition in microvesicles. Erythrocyte-derived microvesi-
cles from Jak2V617F HC-EC mice were incubated for 1 hour with an irre-
versible MPO inhibitor (MPOi, PF06281355, resuspended in DMSO, 
Sigma-Aldrich) diluted in PBS (5 mol/L final concentration). Then, the 
same amount of annexin V–positive erythrocyte-derived microvesicles 
(JAK2WT, JAK2V617F, and JAK2V617F with MPOi) were washed in PBS and 
centrifuged at 20,500 g for 2 hours. The pellet containing the microve-
sicles was then resuspended in endothelial cell basic medium (Pro-
moCell). HUVECs (single donor; PromoCell, C-12200, lot 445Z011) 
were then incubated for 2 hours at 37°C with these microvesicles. At 
the end of the incubation, and without washing cells, ROS genera-
tion was assessed using CellROX, as described above. After rinsing 
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fy cell nuclei. Images were acquired using a Leica SP8 confocal micro-
scope at ×600 magnification.
Statistics. For cumulative dose-response curves, data are expressed 
as mean with SEM and were compared using an ANOVA for repeated 
measures. Other data are expressed as median with IQR (blood cell 
count and spleen weight) and were compared using the Mann-Whit-
ney U test. All tests were 2 sided, and differences were considered sig-
nificant when P was less than 0.05. Data handling and analysis were 
performed with GraphPad Prism Software.
Study approval. Experiments were conducted according to French 
veterinary guidelines and those formulated by the European Com-
munity for experimental animal use (L358-86/609EEC), and were 
approved by the French Ministry of Agriculture (A75-15-32). The 
Institutional Animal Care and Use Committee at Inserm (Université 
Paris–Descartes, Paris, France, CEEA-17-053) approved all animal 
experiments. All donors gave written informed consent to participate 
in the study. Human study was performed in accordance with the ethi-
cal guidelines of the 1975 Declaration of Helsinki and was approved by 
the Institutional Review Board (Comités de protection des personnes 
[CPP], Ile de France IV, Paris, France).
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intense ions were subjected to Orbitrap for further fragmentation via 
high-energy collision dissociation (HCD) activation and a resolution 
of 15,000, with the intensity threshold kept at 1.3 × 105. We selected 
ions with charge state from 2+ to 6+ for screening. Normalized collision 
energy (NCE) was set at 27 and a dynamic exclusion of 40 seconds.
For identification, data were searched against the Mus musculus 
one gene one protein (UP000000589_10090) UniProt database and 
a databank of the common contaminants using SEQUEST HT through 
Proteome Discoverer (version 2.2, Thermo Fisher Scientific). Enzyme 
specificity was set to trypsin, and a maximum of 2 missed cleavage 
sites were allowed. Oxidized methionine and N-terminal acetylation 
were set as variable modifications. Maximum allowed mass deviation 
was set to 10 ppm for monoisotopic precursor ions and 0.02 Da for MS/
MS peaks. The resulting files were further processed using myProMS 
(58) v3.6. FDR calculation used Percolator (59) and was set to 1% at 
the peptide level for the whole study. The label-free quantification was 
performed by peptide extracted ion chromatograms (XICs) comput-
ed with MassChroQ version 2.2 (60). For protein quantification, XICs 
from proteotypic peptides shared by compared conditions (TopN 
matching) with 2 missed cleavages were used. Median and scale nor-
malization was applied on the total signal to correct the XICs for each 
biological replicate. To estimate the significance of the change in pro-
tein abundance, a linear model (adjusted on peptides and biological 
replicates) was performed, and P values were adjusted with a Benja-
mini-Hochberg FDR procedure with a control threshold set to 0.05.
The mass spectrometry proteomics data were deposited into Pro-
teomeXchange via the PRIDE database (61) partner repository (data 
set identifier PXD014451).
Western blot on erythrocyte-derived microvesicles. Erythrocyte- 
derived microvesicles generated as mentioned above were centrifuged 
at 20,500 g for 2 hours and then lysed in 100 μL RIPA buffer contain-
ing 150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.4, 2 mmol/L EDTA, 
0.5% sodium deoxycholate, 0.2% SDS, 2 mmol/L activated orthova-
nadate, complete protease inhibitor cocktail tablet (Complete Mini, 
Roche), and complete phosphatase inhibitor cocktail tablet (Roche). 
Protein content was quantified using the Micro BCA Protein Assay Kit 
(Thermo Fisher Scientific). Equal loading was checked using Ponceau 
red solution. Membranes were incubated with primary antibodies 
(1:1000) (anti-GP91, BD, 611415; anti-GSTT1, Abcam, 199337; anti-
MPO, Abcam, 45977). After secondary antibody incubation (anti-rat, 
Cell Signaling Technology, 1:1000; anti-rabbit or anti-mouse, Amersh-
am, GE Healthcare, 1:3000), immunodetection was performed using 
an enhanced chemiluminescence kit (Immun-Star WesternC kit, Bio-
Rad). Bands were revealed using the LAS-4000 imaging system (GE 
Healthcare Life Sciences). Values reported from Western blots were 
obtained by band density analysis with ImageJ software and expressed 
as the ratio of protein of interest to Ponceau.
Uptake of microvesicles by endothelial cells. Erythrocyte-derived 
microvesicles were stained with PKH26 dye (Sigma-Aldrich) diluted 
in PBS following the manufacturer’s instructions, washed in PBS, and 
then centrifuged at 20,500 g for 2 hours. The 20,500-g supernatant 
was used for control experiments. Murine endothelial cells (the cell 
line SVEC4-10, CRL-2181, ATCC, lot 70008729) were then incubated 
with these stained microvesicles or an equal volume of the 20,500-
g supernatant. After 2 hours at 37°C, cells were washed 3 times with 
DMEM (Gibco). Cells were then fixed in 4% PFA for 5 minutes and 
then costained with DAPI (0.1 g/mL, Sigma-Aldrich) in order to identi-
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